On June 4, 2026 Syndax Pharmaceuticals, Inc. ("Syndax") (NASDAQ: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, reported to have entered into privately negotiated subscription agreements for the issuance of $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 (the "Notes"). The sale of the Notes is expected to close on June 10, 2026, subject to customary closing conditions. J. Wood Capital Advisors LLC is acting as sole placement agent in connection with the private placement of the Notes (the "private placement").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Syndax estimates that the net proceeds from the private placement will be approximately $243 million, after deducting the placement agent’s fees and estimated expenses payable by Syndax. Syndax expects to use the net proceeds from the private placement for general corporate purposes, including working capital, research and development expenditures, commercialization activity expenditures and business development expenditures.

The Notes will be senior unsecured obligations of Syndax and will accrue interest payable semiannually in arrears on June 15 and December 15 of each year, beginning on December 15, 2026 at a rate of 2.25%. The Notes will mature on June 15, 2031, unless earlier converted, redeemed or repurchased.

Noteholders may convert all or any portion of their Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2031, only upon the occurrence of certain circumstances. On or after March 15, 2031, until the close of business on the second scheduled trading day immediately preceding the maturity date, the noteholders may convert all or any portion of their Notes at any time.

Upon conversion, Syndax will pay or deliver, as the case may be, cash, shares of Syndax’s common stock, par value $0.0001 per share (the "common stock"), or a combination of cash and shares of common stock, at Syndax’s election. The conversion rate will initially be 40.3894 shares of common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $24.76 per share of common stock). The initial conversion price of the Notes represents a premium of approximately 35% over the last reported sale price of the common stock on the Nasdaq Global Select Market on June 3, 2026. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date of the Notes or if Syndax delivers a notice of redemption, Syndax will, in certain circumstances, increase the conversion rate for a noteholder who elects to convert its Notes in connection with such a corporate event or notice of redemption, as the case may be.

Syndax may not redeem the Notes prior to June 20, 2029. Syndax may redeem for cash all or any portion of the Notes (subject to certain limitations), at Syndax’s option, on a redemption date on or after June 20, 2029 if the last reported sale price of the common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which Syndax provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

If Syndax undergoes a "fundamental change" (as defined in the indenture that will govern the Notes), then, subject to certain conditions and limited exceptions, noteholders may require Syndax to repurchase for cash all or any portion of their Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

Neither the Notes, nor the shares of common stock issuable upon conversion of the Notes, if any, have been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and unless so registered, may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws.

This press release is neither an offer to sell nor a solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation or sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Syndax, JUN 4, 2026, View Source [SID1234666439])

On June 4, 2026 Ona Therapeutics ("Ona"), a global biopharmaceutical company pioneering first-in-class antibody-drug conjugates (ADCs) to address treatment-resistant cancers, reported the closing of an oversubscribed $86.6 million Series B financing. The round was co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Alta Life Sciences, Asabys Partners, Bpifrance, as part of the InnoBio investment strategy, CDTI through SICC Innvierte, FundPlus NV and Ysios Capital.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The proceeds will be used to advance the clinical development of Ona’s lead program, ONA-255, a first-in-class ADC initially focused on breast cancer, and to progress ONA-389, a second first-in-class ADC targeting colorectal cancer. ONA-255 is designed to address treatment-resistant tumor biology through a differentiated mechanism aimed at improving the therapeutic index compared to earlier approaches. ONA-389 will advance toward first-in-human studies, expanding Ona’s pipeline in indications with significant unmet need. Ona Therapeutics currently retains full worldwide commercial rights to all its assets.

Valerie Vanhooren, PhD, Co-Founder and Chief Executive Officer at Ona Therapeutics, said: "The oversubscribed Series B marks an important step to advancing ONA-255 toward clinical proof of concept in breast cancer, while progressing early clinical development activities for ONA-389 in colorectal cancer. We are proud to have assembled a high-quality syndicate of investors who share our conviction in the differentiated science behind Ona’s novel targets and their potential to address drug resistance. Supported by a highly experienced and talented team, this financing strengthens our commitment to tackling hard-to-treat cancers through meaningful innovation and addressing the significant unmet need faced by patients with limited treatment options."

Jose Mesa, Partner at Columbus Venture Partners, and incoming Board member at Ona Therapeutics, remarked: "At Columbus, we look for companies that combine world-class science with a clear path to clinical impact. Ona is a strong example of that. Its work on cancer resistance and metastasis addresses one of the most important challenges in oncology, and its pipeline, led by ONA-255 and followed by ONA-389, provides a compelling opportunity to build a differentiated oncology platform. We are delighted to support Valerie and the team in this next stage of growth, bringing Columbus’ experience in developing and scaling innovative oncology companies."

Valérie Calenda, Managing Partner and Head of Innovation at Mérieux Equity Partners, and incoming Board member at Ona Therapeutics, added: "Ona exemplifies the kind of high-impact company we look to partner with: a high-quality team building a compelling and differentiated pipeline, combining deep biological insight with a highly focused development strategy. The strength of Ona’s preclinical data package behind ONA-255, the breadth of opportunity across the pipeline, and the team’s clear vision for translating novel biology into clinically meaningful therapies give us strong confidence in the Company’s long-term potential. We are excited to co-lead this financing and support Ona’s next phase of growth."

Ona is advancing a differentiated ADC pipeline focused on cancers with high unmet medical need. Through its proprietary patient-driven target discovery platform, the Company has identified novel tumor-specific antigens and epitopes that enable highly efficient internalization and targeted payload delivery to cancer cells. This approach is designed to maximize therapeutic activity while minimizing on-target toxicities and addressing key biological mechanisms of resistance in advanced tumors.

The financing comes at a pivotal inflection point in Ona’s growth as the Company enters clinical development and begins generating initial human safety and efficacy data for ONA-255. This momentum is supported by a highly experienced clinical leadership team, including Antoine Yver, Chair of the Board, bringing deep expertise in global oncology drug development; Pamela Klein, Independent Board Member, with extensive experience advancing oncology therapeutics; Aleix Prat, a world-renowned breast cancer oncologist and Chair of the Advisory Board; and Jutta Amersdorffer, Chief Medical Officer, leading clinical strategy and execution. Together, this leadership team positions Ona strongly to deliver on key milestones and advance its innovative pipeline for patients.

In connection with the financing, Jose Mesa, Partner at Columbus Venture Partners; Valérie Calenda, Managing Partner at Mérieux Equity Partners; and Eva Van Overmeire, Senior Investment Manager at Korys, will join Ona’s Board of Directors.

(Press release, Ona Therapeutics, JUN 4, 2026, View Source [SID1234666456])

On June 4, 2026 Vycellix, Inc., a biotechnology company developing next-generation allogeneic natural killer (NK) cell-based therapies designed to overcome the risk of immune rejection and redefine functional persistence with durability, reported the Company will attend a series of upcoming investor and partnering meetings to share progress reports on the Company’s universal cell therapy platforms and product candidates targeting multiple myeloma, acute myeloid leukemia and urothelial cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vycellix is attending:

June 8-9: U.S. Department of Commerce Certified Trade Mission to Norway in Oslo
June 11-14: European Hematology Association (EHA) (Free EHA Whitepaper) 2026 Congress in Stockholm
June 22-25: BIO International Convention in San Diego (Florida Pavilion, Booth# 1319)
To request a meeting with Vycellix at any of these events, please contact Doug Calder at [email protected].

Vycellix recently announced the successful completion of pre-clinical development for its universal cell engineering platform (VY-UC) with rigorous studies across many donor cell types proving robust immune evasion with functional persistence. The Company is now preparing for first-in-human clinical validation by seeking regulatory approval in Sweden to initiate a Phase 1 study for its lead VY-UC product candidate, a novel, off-the-shelf NK cell therapy (VNK-101) for patients with relapsed or refractory multiple myeloma.

To view VY-UC mechanism-of-action video, please visit:

View Source

The Company has also generated new data in AML and urothelial cancers supporting further development of its VY-GAGE platform and product candidates to engineer persistent allogeneic effector cells capable of delivering multiple disease-targeting payloads directly to tumor sites using logic-gated CARs and proprietary cleavable linkers, which when tumor-activated, deploy potent multi-antigen engagers, CARs and cytokines. This approach is believed to be safer with optimized target engagement and more effective by limiting cytotoxic killing to only occur within the solid tumor microenvironment.

To view VY-GAGE mechanism-of-action video, please visit:

View Source

(Press release, Vycellix, JUN 4, 2026, View Source;utm_medium=rss&utm_campaign=vycellix-to-provide-universal-cell-cancer-therapy-progress-reports-at-upcoming-investor-partnering-meetings [SID1234666440])

On June 4, 2026 NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, reported the replay availability for its virtual key opinion leader (KOL) event on SIM0505, held following the Company’s ASCO (Free ASCO Whitepaper) 2026 poster presentation of first reported clinical efficacy data from its Phase 1 dose escalation study (June 1, 2026 press release). SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload. The virtual KOL Event is accessible here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event featured:

Beryl Manning-Geist, MD (Emory University)
Ursula Matulonis, MD (NextCure Scientific Advisory Board and Dana-Farber Cancer Institute)
Rakesh Dixit, PhD, DABT (NextCure Scientific Advisory Board)
Discussion centered on first reported clinical efficacy data from the Phase 1 dose escalation study of SIM0505 in ovarian cancer and uterine serous carcinoma (USC), two gynecologic malignancies where effective treatment options remain limited.

About SIM0505 at the Annual Meeting of the American Society for Clinical Oncology (ASCO 2026)

Materials from NextCure’s ASCO (Free ASCO Whitepaper) 2026 activities are available on the Company’s website under Investor Relations, Events & Presentations:

ASCO Poster: View Source
ASCO Press Release: View Source
Virtual KOL Event Replay: View Source
Virtual KOL Event Presentation: View Source
Beryl Manning-Geist, MD is an assistant professor in the Division of Gynecologic Oncology in the Department of Gynecology and Obstetrics at Emory University School of Medicine. Dr. Manning-Geist specializes in treating patients with gynecologic cancers including uterine, ovarian and cervical cancers. She practices at Winship Cancer Institute at Emory Midtown. After working at the National Institutes of Health’s National Cancer Institute, Dr. Manning-Geist attended Emory University School of Medicine on a full scholarship as a Woodruff Scholar. There, she received her MD summa cum laude before completing her residency in obstetrics and gynecology at Harvard University’s Brigham and Women’s Hospital/Massachusetts General Hospital in Boston. She then completed her fellowship in gynecologic oncology at Memorial Sloan Kettering Cancer Center in New York

Ursula Matulonis, MD is Chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. She is the first recipient of the Brock-Wilson Family Chair at the Dana-Farber Cancer Institute. Dr. Matulonis co-leads the Gynecologic Cancer Program within the Dana-Farber/Harvard Cancer Center and the Ovarian Cancer Specialized Program in Research Excellence (SPORE) grant from the National Cancer Institute. Her research is focused on developing new targeted therapies for gynecologic malignancies, with a specific interest in ovarian cancer and endometrial cancer. Dr. Matulonis earned her MD from the Albany Medical College.

Rakesh Dixit, PhD, DABT currently serves as President and CEO of Bionavigen, a biopharmaceutical company specializing in consulting and drug hunting for biologic, cell and gene therapy and small molecule drug development. He is also President and CSO of Regio Biosciences, an AstraZeneca Spinoff company. Dr. Dixit is an accomplished executive, inventor, and scientist with over 30 years of success with top biotechnology and pharmaceutical companies, including Merck, Johnson & Johnson, MedImmune, and AstraZeneca. He was a key contributor to successful approval of biotherapeutics, including five biologics (including antibodies and immunotoxins) and four small molecule pharmaceuticals. He was honored in 2020 by the World ADC Forum with its most prestigious award of Long-Standing Contributor to ADCs.

About SIM0505

SIM0505 is a novel ADC directed to CDH6, featuring a proprietary TOPOi payload. The ADC is designed for broad anti-tumor activity, fast systemic clearance and an improved potential therapeutic window. SIM0505 is being evaluated in an open-label, Phase 1 study (NCT06792552) for the potential treatment of advanced solid tumors, including ovarian cancer, with an emphasis on PROC. The U.S. Food and Drug Administration granted Fast Track Designation to SIM0505 for the treatment of PROC. NextCure holds exclusive global rights for SIM0505, excluding China, Hong Kong, Macau, and Taiwan which are retained by Simcere Zaiming.

(Press release, NextCure, JUN 4, 2026, View Source [SID1234666457])

On June 4, 2026 Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, reported that its collaboration partner, PeriNess Ltd. (PeriNess), has informed the Company that it received formal approval from the Israeli Ministry of Health and the respective Institutional Review Board to conduct an exploratory clinical study of a combination systemic DNase I with anti-CD19 CAR T Cells in large B cell lymphoma (LBCL) patients. This approval follows positive preclinical results that demonstrated significant improvement of CAR T cell expansion and persistence and functionality when combined with DNase I. This combination therapy resulted in improved tumor control, delayed relapse and prolonged survival across multiple preclinical models of leukemia and lymphoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the approved clinical study protocol, 12 LBCL patients with stable or progressive disease prior to lymphodepletion therapy are intended to be treated with CAR T cells targeting CD19 (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) in combination with DNase I (50-ml IV infusion dose, 1.0 mg/kg IV on Days 0,3,6,10 and 15 after CAR T cells infusion). Clinical efficacy is intended to be evaluated by the Objective Response Rate (ORR) at 1 and 3 months post CAR T infusion, duration of response (DOR), disease control rate (DCR) and overall survival (OS) at 12 months post CAR T cells infusion. We believe the study has the potential for a translational component with a complex assessment of biomarker response and analysis of anti-CD19 CAR T expansion and persistence.

Dr. Ron Ram, Professor of Medicine and Head of the Bone Marrow Transplantation Unit at the Sourasky Center, has initiated the study as the principal investigator and all work is intended to be conducted at Sourasky Center in Israel.

"Progression of LBCL is the major obstacle for the success of CAR T therapies, with approximately 50-60% of the patients relapsing in the first year, and approximately 30-45% within 3 months after CAR T infusion, depending on the CAR T product used. While patients with partial or complete response before CAR T infusion have a 1-year progression free survival of approximately 60-80%, those with stable or progressive disease at the time of CAR T infusion have a dismal 1-year progression free survival of approximately 20-30%," commented Dr. Ram "Preclinical data generated over the last few years confirms that accumulation of cell-free chromatin and neutrophil extracellular traps (NETs) within the tumor microenvironment represents a general mechanism of CAR T-cell dysfunction through induction of exhaustion, immunosuppression and impaired expansion and this mechanism is targetable by DNase I. The goal of this clinical study is to improve clinical response by administering DNase I to abrogate the negative effects of cell-free chromatin and NETs on the performance of immune system and CAR T cells."

Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute and a member of Xenetic’s Scientific Steering Committee, added, "CAR T cell treatment induces intensive tumor-cell death and inflammation within the tumor over a short period of time, resulting in massive release of cell-free chromatin and neutrophil extracellular traps (NETs) into the tumor microenvironment. This extracellular DNA burden acts as a major stress factor that accelerates CAR T cell dysfunction and exhaustion, creating a potent negative feedback loop that limits durable efficacy. DNase I disrupts this loop by degrading cell-free chromatin and NETs, thereby improving CAR T cell fitness, preserving cytotoxicity and functional persistence and reducing exhaustion markers, including PD-1, LAG-3, and TIM-3. In our preclinical models, these effects were associated with more durable tumor control following repeated tumor re-challenge, with no tumor regrowth observed in DNase I-treated animals under conditions where tumor progression occurred in the control group. Importantly, unlike conventional strategies that seek to improve CAR T cells primarily through additional cell engineering, our approach is designed to improve the battlefield itself by removing key extracellular barriers to CAR T cell function. We believe the planned study at Tel Aviv Sourasky Medical Center is particularly meaningful given the institution’s longstanding leadership in CAR T-cell therapy and immuno-oncology innovation, both in Israel and internationally. As a pioneer in the development, clinical validation and early adoption of advanced cellular therapies, Sourasky Center combines elite clinical expertise, cutting-edge translational research infrastructure and a proven ability to rapidly translate scientific discoveries into innovative patient treatments, making it an ideal institution to lead this exploratory clinical study."

(Press release, Xenetic Biosciences, JUN 4, 2026, View Source [SID1234666442])